Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 218 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Company Gives Cancer Patient a New HVAC System After Treatment and... March 8, 2019 How Running and Training for a Marathon Helped Me Cope After... August 22, 2023 Strict Safety Measures in Austria Results in Low SARS-CoV-2 Detection Rate... August 17, 2020 Girls Become Best Friends In Hospital, Reunite Years Later For “Survivors”... March 22, 2019 Load more HOT NEWS Immunotherapy approved for some people with oesophageal cancer on NHS in... 10 Things About You That Change When You Lose Your Parents Despite Proven Safety of HPV Vaccines, More Parents Have Concerns FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma
